Pharmacokinetic/Pharmacodynamic Analysis of Standard- and High-Dose Rifampicin to Predict Safety, Completion, and Tolerability of Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial
Clinical Infectious Diseases · 19.11.2026
DOI: 10.1093/cid/ciag647 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 19.11.2026. Verfasst von Fajri Gafar und 24 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Rifampicin-based tuberculosis preventive therapy (TPT) may shorten treatment duration, but substantial interindividual pharmacokinetic variability may lead to different safety and tolerability profiles at the same dose. We performed pharmacokinetic/pharmacodynamic analyses of standard- and high-dose rifampicin to predict safety, completion, and tolerability.
Methods
We analyzed data from 1,368 adults and adolescents enrolled in the 2R2 trial comparing two months of rifampicin at 20 or 30 mg/kg/day with four months at 10 mg/kg/day. A population pharmacokinetic model developed from 440 participants was used to predict rifampicin exposure for all participants. Missing exposure metrics were imputed using 1,000 simulated datasets. Exposure-response relationships were evaluated using multivariable logistic regression models fitted within imputed datasets, with coefficients and standard errors pooled across imputations.
Results
A two-fold increase in total rifampicin exposure (AUC0-24) was associated with higher odds of protocol-defined adverse events (AEs) requiring permanent discontinuation (aOR 1.88, 95% CI 1.25−2.81), discontinuation unrelated to AEs (aOR 1.42, 95% CI 1.15−1.75), and tolerability symptoms potentially related to AEs without discontinuation (aOR 1.48, 95% CI 1.18−1.86); similar patterns were observed for peak concentration (Cmax). Higher AUC0-24 and Cmax were also associated with grade 1−2 and grade 3−4 AEs, rash/allergy/hypersensitivity, gastrointestinal intolerance, and early discontinuation, with no significant association for hepatotoxicity. Exposure-based models showed slightly better discriminatory performance than dose-based models in predicting safety.
Conclusion
Higher rifampicin exposure was associated with worse safety, completion, and tolerability in TPT. Larger efficacy trials are needed to determine the optimal dose to achieve sufficient exposure, alongside investigation of therapeutic drug monitoring to avoid excessive exposure.
Zitieren
APA
Gafar, F., Svensson, E. M., Yunivita, V., Fregonese, F., Fisher, D., Fox, G. J., Nguyen, T. A., Nguyen, B. H., Johnston, J., Long, R., Apriani, L., Valiquette, C., Aarnoutse, R. E., Ruslami, R., Menzies, D., Barss, L., Lim, R. K., Bedingfield, N., Benedetti, A., …, & Nhung, N. V. (2026). Pharmacokinetic/Pharmacodynamic Analysis of Standard- and High-Dose Rifampicin to Predict Safety, Completion, and Tolerability of Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag647
Vancouver
Gafar F, Svensson EM, Yunivita V, Fregonese F, Fisher D, Fox GJ, et al. Pharmacokinetic/Pharmacodynamic Analysis of Standard- and High-Dose Rifampicin to Predict Safety, Completion, and Tolerability of Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag647
BibTeX
@article{Gafar2026,
author = {Gafar, Fajri and Svensson, Elin M and Yunivita, Vycke and Fregonese, Federica and Fisher, Dina and Fox, Greg J and Nguyen, Thu Anh and Nguyen, Binh Hoa and Johnston, James and Long, Richard and Apriani, Lika and Valiquette, Chantal and Aarnoutse, Rob E and Ruslami, Rovina and Menzies, Dick and Barss, Leila and Lim, Rachel K and Bedingfield, Nancy and Benedetti, Andrea and Gibson, Diana and Chiang, Victor and Cook, Victoria J and Flores, Eri and Paulsen, Catherine and Nhung, Nguyen Viet},
title = {Pharmacokinetic/Pharmacodynamic Analysis of Standard- and High-Dose Rifampicin to Predict Safety, Completion, and Tolerability of Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag647}
}
EUVIMED